{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:51:28Z","timestamp":1780685488977,"version":"3.54.1"},"posted":{"date-parts":[[2023,8,28]]},"group-title":"Cancer Biology","reference-count":88,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>The Wnt\/\u03b2-catenin pathway\u2019s significance in cancer initiation, progression, and stem cell biology underscores its therapeutic potential, yet clinical application of Wnt inhibitors remains limited due to challenges posed by off-target effects and complex crosstalk with other pathways. In this study, we leveraged the zebrafish model to perform a robust and rapid drug screening of 773 FDA-approved compounds to identify Wnt\/\u03b2-catenin inhibitors with minimal toxicity. Utilizing zebrafish expressing a Wnt reporter, we identified several drugs that suppressed Wnt signaling without compromising zebrafish development. The efficacy of the top hit, Erlotinib, extended to human cells, where it blocked Wnt\/\u03b2-catenin signaling downstream of the destruction complex. Notably, Erlotinib treatment reduced self-renewal in human T-cell Acute Lymphoblastic Leukemia cells, which are known to rely on active \u03b2-catenin signaling for maintenance of leukemia-initiating cells. Erlotinib also reduced leukemia-initiating cell frequency and delayed disease formation in zebrafish models. This study underscores zebrafish\u2019s translational potential in drug discovery and repurposing, and highlights a new use for Erlotinib as a Wnt inhibitor for cancers driven by aberrant Wnt\/\u03b2-catenin signaling.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Highlights<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>\n                        Zebrafish-based drug screening offers an inexpensive and robust platform for identifying compounds with high efficacy and low toxicity\n                        <jats:italic>in vivo<\/jats:italic>\n                        .\n                      <\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Erlotinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, emerged as a potent and promising Wnt inhibitor with effects in both zebrafish and human cell-based Wnt reporter assays.<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>The identification of Erlotinib as a Wnt inhibitor underscores the value of repurposed drugs in developing targeted therapies to disrupt cancer stemness and improve clinical outcomes<\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Graphical Abstract<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"555200v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.1101\/2023.08.28.555200","type":"posted-content","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T03:00:10Z","timestamp":1693278010000},"source":"Crossref","is-referenced-by-count":2,"title":["Zebrafish Drug Screening Identifies Erlotinib as an Inhibitor of Wnt\/\u03b2-Catenin Signaling and Self-Renewal in T-cell Acute Lymphoblastic Leukemia"],"prefix":"10.64898","author":[{"given":"Majd A.","family":"Al-Hamaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna H.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan G.","family":"Haney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Arvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Sampathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Wimsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9464-3784","authenticated-orcid":false,"given":"Jessica S.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023090104501330000_2023.08.28.555200v1.1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/bs.pmbts.2017.11.002","article-title":"Wnt signaling in hematological malignancies","volume":"153","year":"2018","journal-title":"Progress in molecular biology and translational science"},{"key":"2023090104501330000_2023.08.28.555200v1.2","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3389\/fimmu.2019.02854","article-title":"WNT signaling in tumors: the way to evade drugs and immunity","volume":"10","year":"2019","journal-title":"Frontiers in immunology"},{"key":"2023090104501330000_2023.08.28.555200v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.304"},{"key":"2023090104501330000_2023.08.28.555200v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.02.006"},{"key":"2023090104501330000_2023.08.28.555200v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2009.06.016"},{"key":"2023090104501330000_2023.08.28.555200v1.6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.20.010403.113126"},{"key":"2023090104501330000_2023.08.28.555200v1.7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.biopha.2018.11.082","article-title":"Therapeutic potential of targeting the Wnt\/\u03b2-catenin signaling pathway in colorectal cancer","volume":"110","year":"2019","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2023090104501330000_2023.08.28.555200v1.8","doi-asserted-by":"crossref","first-page":"110851","DOI":"10.1016\/j.biopha.2020.110851","article-title":"WNT\/\u03b2-catenin signaling in the development of liver cancers","volume":"132","year":"2020","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2023090104501330000_2023.08.28.555200v1.9","doi-asserted-by":"publisher","DOI":"10.2174\/138945010792006780"},{"key":"2023090104501330000_2023.08.28.555200v1.10","first-page":"1","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","year":"2020","journal-title":"Journal of hematology & oncology"},{"key":"2023090104501330000_2023.08.28.555200v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2007.02.007"},{"issue":"7","key":"2023090104501330000_2023.08.28.555200v1.12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/cancers8070060","article-title":"Wnt signaling in cancer stem cell biology","volume":"8","year":"2016","journal-title":"Cancers"},{"key":"2023090104501330000_2023.08.28.555200v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2013.01.004"},{"issue":"2","key":"2023090104501330000_2023.08.28.555200v1.14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mc.23277","article-title":"Breast cancer stem cells: A review of their characteristics and the agents that affect them","volume":"60","year":"2021","journal-title":"Molecular carcinogenesis"},{"key":"2023090104501330000_2023.08.28.555200v1.15","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.091125"},{"key":"2023090104501330000_2023.08.28.555200v1.16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-0184"},{"key":"2023090104501330000_2023.08.28.555200v1.17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay7522"},{"issue":"3","key":"2023090104501330000_2023.08.28.555200v1.18","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1038\/bcj.2014.12","article-title":"Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia","volume":"4","year":"2014","journal-title":"Blood cancer journal"},{"key":"2023090104501330000_2023.08.28.555200v1.19","unstructured":"Panelli, P. , et al., Non-canonical \u03b2-Catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia. Blood, 2022."},{"issue":"25","key":"2023090104501330000_2023.08.28.555200v1.20","first-page":"3917","article-title":"Leukemia stem cells in T-ALL require active Hif1\u03b1 and Wnt signaling. Blood","volume":"125","year":"2015","journal-title":"The Journal of the American Society of Hematology"},{"issue":"2","key":"2023090104501330000_2023.08.28.555200v1.21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","article-title":"Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond \u03b2-catenin and the destruction complex","volume":"52","year":"2020","journal-title":"Experimental & Molecular Medicine"},{"key":"2023090104501330000_2023.08.28.555200v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3470"},{"issue":"8","key":"2023090104501330000_2023.08.28.555200v1.23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/cells12081110","article-title":"A New Wave of Targeting \u2018Undruggable\u2019Wnt Signaling for Cancer Therapy: Challenges and Opportunities","volume":"12","year":"2023","journal-title":"Cells"},{"issue":"15","key":"2023090104501330000_2023.08.28.555200v1.24","doi-asserted-by":"crossref","first-page":"20395","DOI":"10.18632\/oncotarget.7954","article-title":"CWP232228 targets liver cancer stem cells through Wnt\/\u03b2-catenin signaling: a novel therapeutic approach for liver cancer treatment","volume":"7","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"2023090104501330000_2023.08.28.555200v1.25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s11626-015-9931-x","article-title":"PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt\/\u03b2-catenin signaling pathway","volume":"51","year":"2015","journal-title":"In Vitro Cellular & Developmental Biology-Animal"},{"key":"2023090104501330000_2023.08.28.555200v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4627"},{"key":"2023090104501330000_2023.08.28.555200v1.27","unstructured":"Sharma, A. and A. Saneja , Zebrafish as a powerful alternative model organism for preclinical investigation of nanomedicines. Drug Discovery Today, 2022."},{"issue":"1","key":"2023090104501330000_2023.08.28.555200v1.28","first-page":"1","article-title":"Spatiotemporal imaging and pharmacokinetics of fluorescent compounds in zebrafish eleuthero-embryos after different routes of administration","volume":"11","year":"2021","journal-title":"Scientific reports"},{"issue":"5","key":"2023090104501330000_2023.08.28.555200v1.29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/neuonc\/noab264","article-title":"Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts","volume":"24","year":"2022","journal-title":"Neuro-oncology"},{"key":"2023090104501330000_2023.08.28.555200v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2015.11.021"},{"key":"2023090104501330000_2023.08.28.555200v1.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085439"},{"key":"2023090104501330000_2023.08.28.555200v1.32","doi-asserted-by":"crossref","unstructured":"Haney, M.G. , L.H. Moore , and J.S. Blackburn , Drug screening of primary patient derived tumor xenografts in zebrafish. JoVE (Journal of Visualized Experiments), 2020(158): p. e60996.","DOI":"10.3791\/60996"},{"issue":"1","key":"2023090104501330000_2023.08.28.555200v1.33","first-page":"1","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","year":"2020","journal-title":"Signal transduction and targeted therapy"},{"key":"2023090104501330000_2023.08.28.555200v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2012.07.016"},{"issue":"16","key":"2023090104501330000_2023.08.28.555200v1.35","first-page":"3296","article-title":"High-throughput cell transplantation establishes that tumor-initiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia. Blood","volume":"115","year":"2010","journal-title":"The Journal of the American Society of Hematology"},{"key":"2023090104501330000_2023.08.28.555200v1.36","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00373-15"},{"issue":"24","key":"2023090104501330000_2023.08.28.555200v1.37","doi-asserted-by":"crossref","first-page":"11348","DOI":"10.1021\/acs.jmedchem.9b01685","article-title":"An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors","volume":"62","year":"2019","journal-title":"J Med Chem"},{"issue":"12","key":"2023090104501330000_2023.08.28.555200v1.38","doi-asserted-by":"crossref","first-page":"101795","DOI":"10.1016\/j.isci.2020.101795","article-title":"Epigenetic Regulation of Wnt Signaling by Carboxamide-Substituted Benzhydryl Amines that Function as Histone Demethylase Inhibitors","volume":"23","year":"2020","journal-title":"iScience"},{"issue":"2","key":"2023090104501330000_2023.08.28.555200v1.39","doi-asserted-by":"crossref","first-page":"100433","DOI":"10.1016\/j.xpro.2021.100433","article-title":"Protocol for rapid assessment of the efficacy of novel Wnt inhibitors using zebrafish models","volume":"2","year":"2021","journal-title":"STAR protocols"},{"issue":"12","key":"2023090104501330000_2023.08.28.555200v1.40","doi-asserted-by":"crossref","first-page":"101795","DOI":"10.1016\/j.isci.2020.101795","article-title":"Epigenetic regulation of Wnt signaling by carboxamide-substituted benzhydryl amines that function as histone demethylase inhibitors","volume":"23","year":"2020","journal-title":"Iscience"},{"key":"2023090104501330000_2023.08.28.555200v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.032"},{"key":"2023090104501330000_2023.08.28.555200v1.42","doi-asserted-by":"crossref","unstructured":"Blackburn, J.S. , S. Liu , and D.M. Langenau , Quantifying the frequency of tumor-propagating cells using limiting dilution cell transplantation in syngeneic zebrafish. JoVE (Journal of Visualized Experiments), 2011(53): p. e2790.","DOI":"10.3791\/2790-v"},{"key":"2023090104501330000_2023.08.28.555200v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2009.06.008"},{"key":"2023090104501330000_2023.08.28.555200v1.44","doi-asserted-by":"publisher","DOI":"10.1038\/nature08356"},{"key":"2023090104501330000_2023.08.28.555200v1.45","first-page":"1","article-title":"Cytotoxicity and activation of the Wnt\/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors","volume":"7","year":"2014","journal-title":"BMC research notes"},{"key":"2023090104501330000_2023.08.28.555200v1.46","doi-asserted-by":"crossref","unstructured":"Stoick-Cooper, C.L. , et al., Distinct Wnt signaling pathways have opposing roles in appendage regeneration. 2007.","DOI":"10.1242\/dev.001123"},{"issue":"4","key":"2023090104501330000_2023.08.28.555200v1.47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1527-3466.2004.tb00146.x","article-title":"Candesartan","volume":"22","year":"2004","journal-title":"Cardiovasc Drug Rev"},{"key":"2023090104501330000_2023.08.28.555200v1.48","first-page":"863","article-title":"Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer","volume":"20","year":"2021","journal-title":"Excli j"},{"issue":"1","key":"2023090104501330000_2023.08.28.555200v1.49","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1038\/s41598-021-89668-5","article-title":"A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3)","volume":"11","year":"2021","journal-title":"Scientific Reports"},{"issue":"4","key":"2023090104501330000_2023.08.28.555200v1.50","first-page":"739","article-title":"Effect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells","volume":"9","year":"2013","journal-title":"Arch Med Sci"},{"key":"2023090104501330000_2023.08.28.555200v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.10.006"},{"issue":"21","key":"2023090104501330000_2023.08.28.555200v1.52","first-page":"2665","article-title":"Cardiovascular drugs","volume":"102","year":"2000","journal-title":"Dofetilide. Circulation"},{"key":"2023090104501330000_2023.08.28.555200v1.53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.podrm.2019.10.004","article-title":"Erlotinib","volume":"45","year":"2020","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"6","key":"2023090104501330000_2023.08.28.555200v1.54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/ERC-22-0022","article-title":"Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma","volume":"29","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2023090104501330000_2023.08.28.555200v1.55","unstructured":"Correa, R. , Q. Rodriguez , and T.M. Nappe, Glipizide. 2017."},{"key":"2023090104501330000_2023.08.28.555200v1.56","doi-asserted-by":"crossref","first-page":"27819","DOI":"10.1038\/srep27819","article-title":"Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis","volume":"6","year":"2016","journal-title":"Sci Rep"},{"issue":"59","key":"2023090104501330000_2023.08.28.555200v1.57","doi-asserted-by":"crossref","first-page":"100021","DOI":"10.18632\/oncotarget.21754","article-title":"Glipizide sensitizes lung cancer cells to TRAIL-induced apoptosis via Akt\/mTOR\/autophagy pathways","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"2023090104501330000_2023.08.28.555200v1.58","doi-asserted-by":"publisher","DOI":"10.3747\/co.v18i1.708"},{"key":"2023090104501330000_2023.08.28.555200v1.59","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602215"},{"issue":"6","key":"2023090104501330000_2023.08.28.555200v1.60","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","year":"2020","journal-title":"Cell Oncol (Dordr"},{"issue":"1","key":"2023090104501330000_2023.08.28.555200v1.61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12967-016-0875-z","article-title":"Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin","volume":"14","year":"2016","journal-title":"J Transl Med"},{"key":"2023090104501330000_2023.08.28.555200v1.62","doi-asserted-by":"publisher","DOI":"10.1177\/106002809302700915"},{"key":"2023090104501330000_2023.08.28.555200v1.63","first-page":"1","article-title":"Wnt3a: functions and implications in cancer","volume":"34","year":"2015","journal-title":"Chinese journal of cancer"},{"key":"2023090104501330000_2023.08.28.555200v1.64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505259102"},{"key":"2023090104501330000_2023.08.28.555200v1.65","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2137"},{"key":"2023090104501330000_2023.08.28.555200v1.66","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0626"},{"key":"2023090104501330000_2023.08.28.555200v1.67","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fonc.2018.00347","article-title":"Sphere-formation assay: three-dimensional in vitro culturing of prostate cancer stem\/progenitor sphere-forming cells","volume":"8","year":"2018","journal-title":"Frontiers in oncology"},{"key":"2023090104501330000_2023.08.28.555200v1.68","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2014.573"},{"issue":"4","key":"2023090104501330000_2023.08.28.555200v1.69","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1254\/jphs.13025FP","article-title":"Multi-drug\u2013resistant cells enriched from chronic myeloid leukemia cells by doxorubicin possess tumor-initiating\u2013cell properties","volume":"122","year":"2013","journal-title":"Journal of pharmacological sciences"},{"issue":"21","key":"2023090104501330000_2023.08.28.555200v1.70","first-page":"2553","article-title":"Metabolism in stem cell\u2013driven leukemia: parallels between hematopoiesis and immunity. Blood","volume":"141","year":"2023","journal-title":"The Journal of the American Society of Hematology"},{"issue":"8","key":"2023090104501330000_2023.08.28.555200v1.71","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1002\/jcp.26265","article-title":"The roles of Wnt\/\u03b2-catenin pathway in tissue development and regenerative medicine","volume":"233","year":"2018","journal-title":"Journal of cellular physiology"},{"key":"2023090104501330000_2023.08.28.555200v1.72","doi-asserted-by":"publisher","DOI":"10.1177\/0192623315621192"},{"key":"2023090104501330000_2023.08.28.555200v1.73","doi-asserted-by":"crossref","first-page":"09636897221075749","DOI":"10.1177\/09636897221075749","article-title":"Lovastatin inhibits RhoA to suppress canonical Wnt\/\u03b2-catenin signaling and alternative Wnt-YAP\/TAZ signaling in colon cancer","volume":"31","year":"2022","journal-title":"Cell Transplantation"},{"key":"2023090104501330000_2023.08.28.555200v1.74","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4233"},{"key":"2023090104501330000_2023.08.28.555200v1.75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0877"},{"key":"2023090104501330000_2023.08.28.555200v1.76","doi-asserted-by":"publisher","DOI":"10.2165\/11586540-000000000-00000"},{"key":"2023090104501330000_2023.08.28.555200v1.77","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11636"},{"issue":"11","key":"2023090104501330000_2023.08.28.555200v1.78","doi-asserted-by":"crossref","first-page":"e22905","DOI":"10.1002\/jbt.22905","article-title":"Doxazosin and erlotinib have anticancer effects in the endometrial cancer cell and important roles in ER\u03b1 and Wnt\/\u03b2-catenin signaling pathways","volume":"35","year":"2021","journal-title":"Journal of Biochemical and Molecular Toxicology"},{"issue":"1","key":"2023090104501330000_2023.08.28.555200v1.79","first-page":"1","article-title":"Convergence between Wnt-\u03b2-catenin and EGFR signaling in cancer","volume":"9","year":"2010","journal-title":"Molecular cancer"},{"issue":"5","key":"2023090104501330000_2023.08.28.555200v1.80","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41388-018-0473-z","article-title":"EGF-induced nuclear localization of SHCBP1 activates \u03b2-catenin signaling and promotes cancer progression","volume":"38","year":"2019","journal-title":"Oncogene"},{"key":"2023090104501330000_2023.08.28.555200v1.81","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208296"},{"issue":"12","key":"2023090104501330000_2023.08.28.555200v1.82","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling","volume":"21","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"13","key":"2023090104501330000_2023.08.28.555200v1.83","first-page":"1597","article-title":"Noncanonical \u03b2-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia. Blood","volume":"141","year":"2023","journal-title":"The Journal of the American Society of Hematology"},{"key":"2023090104501330000_2023.08.28.555200v1.84","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0362"},{"issue":"8","key":"2023090104501330000_2023.08.28.555200v1.85","doi-asserted-by":"crossref","first-page":"e1850","DOI":"10.1038\/cddis.2015.217","article-title":"Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer","volume":"6","year":"2015","journal-title":"Cell death & disease"},{"key":"2023090104501330000_2023.08.28.555200v1.86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clineuro.2018.02.041","article-title":"Crizotinib and erlotinib inhibits growth of c-Met+\/EGFRvIII+ primary human glioblastoma xenografts","volume":"171","year":"2018","journal-title":"Clinical neurology and neurosurgery"},{"key":"2023090104501330000_2023.08.28.555200v1.87","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24416"},{"issue":"1","key":"2023090104501330000_2023.08.28.555200v1.88","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.2011.540799","article-title":"Reviewing the safety of erlotinib in non-small cell lung cancer","volume":"10","year":"2011","journal-title":"Expert opinion on drug safety"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.08.28.555200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:08:29Z","timestamp":1768453709000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.08.28.555200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":88,"URL":"https:\/\/doi.org\/10.1101\/2023.08.28.555200","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.biopha.2023.116013","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,8,28]]},"subtype":"preprint"}}